Baird Medical Enters Egyptian Market with First Successful Bone Tumor Ablation
Rhea-AI Summary
Baird Medical (NASDAQ: BDMD) announced its official launch into the Egyptian market on Nov 3, 2025 with a successful first microwave bone ablation at Ain Shams Specialized Hospital.
The procedure, performed by Dr. Amr Mahmoud, treated a 1 x 1.5 cm bone lesion in a 30-year-old male with left thigh pain and achieved full ablation and marked pain relief, illustrating the Baird MWA system's use in musculoskeletal applications beyond soft tissue.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BDMD declined 9.16%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $46M at that time.
Data tracked by StockTitan Argus on the day of publication.
The landmark case involved a bone ablation performed by Dr. Amr Mahmoud. The patient, a 30-year-old male suffering from left thigh pain, was found to have a 1 x 1.5 cm bone lesion. The MWA procedure was completed safely and effectively, achieving full ablation and providing the patient with significant pain relief.
This case highlights the versatility of the Baird MWA system, demonstrating its capabilities beyond soft tissue treatments into musculoskeletal applications.
"This first procedure at Ain Shams Specialized Hospital marks a major milestone, signifying our entry into
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-enters-egyptian-market-with-first-successful-bone-tumor-ablation-302602251.html
SOURCE BDMD
FAQ
What did Baird Medical (NASDAQ: BDMD) announce on Nov 3, 2025 about Egypt?
Who performed Baird Medical's first bone ablation in Egypt and where?
What was the size and outcome of the bone lesion treated in the BDMD procedure?
Does the Nov 3, 2025 BDMD case show new uses for the Baird MWA system?
Is the Nov 3, 2025 procedure described as safe and effective for the patient?
Will the BDMD announcement on Nov 3, 2025 affect patient access to MWA in Egypt immediately?
